Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets

AIDS

Volumn 24, Issue 3, 2010, Pages 365-371

  Assoumou, Lambert ^a,b   Cozzi Lepri, Alessandro ^c   Brun Vézinet, Françoise ^d   Degruttola, Victor ^e   Kuritzkes, Daniel R ^f   Phillips, Andrew ^c   Zolopa, Andrew ^g   Miller, Veronica ^h   Flandre, Philippe ^a,b   Costagliola, Dominique ^a,b  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d BICHAT HOSPITAL   (France)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g STANFORD UNIVERSITY   (United States)

^h GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Didanosine; Didanosine algorithm; Didanosine genotypic resistance score; Didanosine interpretation system; Didanosine scoring system; Genotypic resistance score; Viral load

Indexed keywords

DIDANOSINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DATA BASE; DRUG EFFICACY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; POPULATION RESEARCH; PRIORITY JOURNAL; SCORING SYSTEM; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; VALIDATION STUDY; VIRUS LOAD;

ADULT; ALGORITHMS; ANTI-HIV AGENTS; DIDANOSINE; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MUTATION; RNA, VIRAL; VIRAL LOAD;

EID: 75649088111     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833338ba     Document Type: Article

References (17)

1. Molina JM, Marcelin AG, Pavie J, Heripret L, De Boever CM, Troccaz M, et al. Didanosine in HIV-1 infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial. J Infect Dis 2005; 191:840-847
2. Stanford University HIV Drug Resistance Database. http:// hivdb.stanford.edu/pages/asi/releaseNotes/
3. Agence Nationale de Recherches sur le SIDA (ANRS). HIV-1 genotypic drug resistance interpretation's algorithms. http:// www.hivfrenchresistance.org/ table.html.
4. Hirsch MS, Brun-Vézinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an international AIDS Society-USA panel. Clin Infect Dis 2003; 37:113-128.
5. Assoumou L, Brun-Vézinet F, Cozzi-Lepri A, Kuritzkes D, Phillips A, Zolopa A, et al. Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response. J Infect Dis 2008; 198:470-480.
6. Boulmé R, Halfon P, Diaz R, et al. Comparative evaluation between five automated resistance interpretation algorithms. Antivir Ther 2001; 6 (Suppl 1):121.
7. St Clair MH, Martin JL, Tudor-Williams G, Bach MC, Vavro CL, King DM, et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991; 253:1557-1559.
8. Larder BA, Bloor S, Kemp SD, Hertogs K, Desmet RL, Miller V, et al. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob Agents Chemother 1999; 43:1961-1967.
9. Winters MA, Shafer RW, Jellinger RA, Mamtora G, Gingeras T, Merigan TC. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Chemother 1997; 41: 757-762.
10. Svarovskaia ES, Margot NA, Bae AS, Waters JM, Goodman D, Zhong L, et al. Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine. J Acquir Immune Defic Syndr 2007; 46:174-180.
11. Forum for Collaborative HIV Research. Standardization and clinical relevance of HIV drug resistance testing. http:// www.hivforum.org/projets/ standardization.html.
12. Hughes MD. Analysis and design issues for studies using censored biomarker measurements with an example of viral load measurements in HIV clinical trials. Stat Med 2000; 19:3171-3191
13. MIXMOD (MIXture MODelling) software 2.1.1. http://www-math.univ-fcomte. fr/mixmod/index.php.
14. Ravela J, Betts BJ, Brun-Vézinet F, Vandamme AM, Descamps D, van Laethem K, et al. HIV-1 protease and reverse transcrip-tase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. J Acquir Immune Defic Syndr 2003; 33:8-14.
15. Marcelin AG, Flandre P, Pavie J, Schmidely N, Wirden M, Lada O, et al. Clinically relevant genotype interpretation of resistance to didanosine. Antimicrob Agents Chemother 2005; 49:1739-1744.
16. Capdepont S, Aurillac-Lavignolle V, Faure M, Dupon M, Morlat P, Ragnaud JM, et al. An additive/substractive genotypic score as a determinant of the virological response to didanosine in HIV-1 infected patients. J Clin Virol 2006; 36:36-42.
17. De Luca A, Di Giambenedetto S, Trotta MP, Colafigli M, Prosperi M, Ruiz L, et al. Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine. J Infect Dis 2007; 196:1645-1653.